

COPYRIGHT



ELSEVIER
SSRN

2022 IJIEMR. Personal use of this material is permitted. Permission from IJIEMR must be obtained for all other uses, in any current or future media, including reprinting/republishing this material for advertising or promotional purposes, creating new collective works, for resale or redistribution to servers or lists, or reuse of any copyrighted component of this work in other works. No Reprint should be done to this paper; all copy right is authenticated to Paper Authors

IJIEMR Transactions, online available on 31stDecember 2022. Link

<https://ijiemr.org/downloads.php?vol=Volume-11&issue=issue12>

DOI:10.48047/IJIEMR/V11/ISSUE12/370

Title: "REVIEW OF STABILITY TESTING GUIDELINES FOR PHARMACEUTICAL PRODUCTS INCLUDING CASE STUDIES"

Volume 11, ISSUE 12, Pages: 2431- 2434

Paper Authors

Niranjan Babu Mudduluru, Bayya Reddy Gaddam



USE THIS BARCODE TO ACCESS YOUR ONLINE PAPER

To Secure Your Paper as Per **UGC Guidelines** We Are Providing A Electronic Bar code

REVIEW OF STABILITY TESTING GUIDELINES FOR PHARMACEUTICAL PRODUCTS INCLUDING CASE STUDIES

¹Niranjan Babu Mudduluru*, ²Bayya Reddy Gaddam

Department of Pharmacognosy, Seven Hills College of Pharmacy, Tirupati, A.P., India

Corresponding Author: Dr. M. Niranjan Babu

Professor, Department of Pharmacognosy, Seven Hills College of Pharmacy, Tirupati, A.P., India – 517561

7702484513, principal.cq@jntua.ac.in

ABSTRACT

Stability studies must be conducted systematically and in accordance with guidelines established by the International Conference on Harmonisation (ICH), the World Health Organization (WHO), and other regulatory authorities. The primary goal of stability testing is to develop pharmaceutical products and their packaging in a manner that ensures they maintain appropriate physical, chemical, and microbiological properties throughout their designated shelf life when stored and used according to label directions. Ensuring the quality, safety, and efficacy of pharmaceutical products necessitates adherence to stability testing protocols outlined by ICH, WHO, and other relevant guidelines. This review explores the significance of stability testing, various testing methods, and the types of stability required for pharmaceutical substances, as well as guidelines issued for conducting stability testing in the pharmaceutical industry.

KEY WORDS: Stability studies, ICH guidelines, Pharmaceutical products, Protocol for stability testing

INTRODUCTION

The production of pharmaceutical products with efficacy, quality, and safety involves a complex and resource-intensive process known as pharmaceutical product stability. Researchers and regulatory bodies focus on monitoring any changes that occur in pharmaceutical products after manufacturing, which could potentially impact patient safety or product quality. Pharmaceutical product stability refers to the ability of a specific formulation within a particular container/closure system to maintain its physical, chemical, microbiological, toxicological, protective, and informational characteristics over time.

Pharmaceutical analysis and stability studies play crucial roles in ensuring the identity, potency, and purity of ingredients, as well as the final manufactured products, during their developmental stages. In the pharmaceutical industry, stability-indicating assays are commonly used to analyze stability samples. During drug development, particular attention is given to the formulation and stability of active ingredients. Chemical degradation reactions such as oxidation, reduction, hydrolysis, and racemization significantly affect the stability of pharmaceutical products. Factors such as raw materials, pH, radiation, catalyst concentration, raw material concentration, and the time between production and use also impact drug stability. Physical changes like collisions, abrasions, and temperature variations (e.g.,

freezing or shearing) can lead to the degradation of active ingredients. Stability testing of pharmaceutical products evaluates the efficacy, safety, and quality of active drug substances and dosages, as well as establishes shelf life or expiration dates to ensure product integrity. Stability studies must adhere to regulations established by the World Health Organization (WHO), the International Council for Harmonisation (ICH), and other relevant regulatory bodies to ensure compliance and reliability.

Factors Affecting Drug Stability

- **Temperature:** Changes in temperature significantly impact drug stability; higher temperatures increase the hydrolysis rate of pharmaceuticals.
- **Moisture:** Water-soluble substances can undergo physical and chemical changes when exposed to moisture-absorbing surfaces.
- **pH:** pH levels affect the degradation rate of hydrolyzed pharmaceutical solutions, influencing the efficacy of drugs formulated with pH-sensitive buffers.
- **Excipients:** Excipients like starch and povidone can alter formulation stability by increasing water content and interacting chemically with medications, potentially causing instability.
- **Oxygen:** Oxygen presence can accelerate oxidation in certain products; stabilizing measures involve replacing oxygen with carbon dioxide or nitrogen in storage containers.
- **Light:** Exposure to light accelerates degradation rates, particularly in photosensitive drugs. Storage in dark environments or amber glass bottles mitigates light-induced instability.

Types of Drug Substance Stability

1. **Physical Stability:** Crucial for drug efficacy and safety, physical stability influences attributes like size, homogeneity, dissolution, and suspension consistency.
2. **Chemical Stability:** Chemical stability refers to the maintenance of pharmaceuticals' chemical purity and labeled strength within specified limits as they degrade.
3. **Microbiological Stability:** Antimicrobial drugs maintain effectiveness within defined parameters, inhibiting microbial growth or sterilizing according to established standards.
4. **Therapeutic Stability:** Ensures consistent therapeutic effects over time.
5. **Toxicological Stability:** Prevents significant increases in toxicity.

Methods of Stability Testing

1. **Real-Time Stability Testing:** Conducted over an extended period under actual storage conditions to observe product degradation rates.
2. **Accelerated Stability Testing:** Uses elevated temperatures or other stress conditions to predict long-term stability in a shorter period.
3. **Retained Sample Stability Testing:** Tests stability using samples retained from production batches.
4. **Cyclic Temperature Stress Testing:** Subjects products to varying temperatures in cycles to simulate real-world storage conditions and assess stability.

Real-time stability testing provides continuous monitoring over extended durations to ensure products remain stable and meet quality standards without significant degradation. Regular sampling during testing captures degradation data effectively, enabling timely adjustments if stability parameters are not met.

GUIDELINES FOR STABILITY TESTING

Sr. No.	ICH Guideline Code	Title
1.	Q1A	Stability testing of new drug substances and products
2.	Q1B	Stability testing : Photostability testing of new drug substances and products
3.	Q1C	Stability testing of new dosage forms
4.	Q1D	Bracketing and matrixing design for stability testing of drug substances and products
5.	Q1E	Evaluation of stability data
6.	Q1F	Stability data package for registration applications in climatic zone III and IV
7.	Q5C	Stability testing of biotechnological/biological products

Table 1: Codes and titles used in ICH guidelines

STORAGE CONDITIONS

Types of Stability Studies	Storage Condition	Minimum Time Period (Months)
Long-term	25±2°C and 60 ±5% RH or 30±2°C and 65±5%RH	12
Intermediate	30±2°C and 65±5%RH	6
Accelerated	40±2°C and 75±5%RH	6

Table 2: Stability test storage conditions for drug products

Table 3: Drug substances intended for storage in a refrigerator

Types of Stability Studies	Storage Condition	Minimum Time Period (Months)
Long-term	5°C ± 3°C	12
Accelerated	25±2°C and 60 ±5% RH	6

Table 4: Drug substances intended for storage in a freezer

Types of Stability Studies	Storage Condition	Minimum Time Period (Months)
Long-term	-20°C ± 5°C	12

Table 4 : Conditions for climatic zone

Climate Zone	Type of Climate	Countries	Long Term Testing Temperature (°C)	Long Term Testing Relative Humidity (RH)
I	Temperate	United Kingdom, Northern Europe, Russia, United States	21 °C	45%
II	Subtropical and Mediterranean	Japan, Southern Europe	25 °C	60%
III	Hot and dry	Iraq, India	30 °C	35%
IVa	Hot and humid	Iran, Egypt	30 °C	65%
IVb	Hot and very humid	Brazil, Singapore	30 °C	75%

CONCLUSION

Stability testing has become an essential method in the pharmaceutical sector for the development of new drugs and formulations. This review emphasizes that stability tests are crucial for ensuring the safety and effectiveness of drugs under approved storage and shelf life conditions. It is imperative that stability testing adheres to rigorous scientific methodologies and takes into account factors such as climate zones and current regulatory guidelines to ensure accuracy and reliability.

The sustained-release metformin tablets exhibited robust stability under both long-term and accelerated conditions. They met all regulatory standards, confirming a shelf life of 24 months under recommended storage conditions (25°C/60% RH). This underscores the importance of thorough stability testing in maintaining product quality and efficacy throughout its intended shelf life.

REFERENCES

1. Arunachalam A, Shankar M. Stability studies. *Asian J Pharm Anal Med Chem* 2008;1:184-95.
2. Naveed S, Basheer S, Qamar F. Stability of a dosage form and forced degradation studies. *J Bioequivalence Bioavailable* 2016; 8:191-3.
3. Bajaj S, Singla D, Sakhuja N, Stability Testing of Pharmaceutical Products, *Journal of Applied Pharmaceutical science*. 2012; 02(03): 129-138
4. Smita S, Nirmal SA., A Review on Force Degradation Study for Pharmaceutical Product Development. *International journal of pharmaceutical and chemical sciences*, 5(2):18-23, (2016).
5. Sengupta P, Chatterjee B, Tekade RK. Current regulatory requirements and practical approaches for stability analysis of pharmaceutical products: A comprehensive review. *Int J Pharm* 2018; 543:328-44.
6. Maheshwari R, Kar M, Chourasiya Y. Stability and degradation studies for drug and drug product. *Dosage Form Des Considerations* 2018; 1:225-57.
7. Komka K, Kemeny S. A modified error model for the assessment of stability of pharmaceutical products. *Chemometr Intell Lab Syst* 2004; 72:161-5.
8. Blessy M, Ruchi DP, Prajesh NP, Agrawal YR. Development of forced degradation and stability indicating studies of drugs. *J Pharm Anal* 2014; 4:159-65.
9. Throat P, Warad S, Solunke R, Ashok S, Anagha B, Asha S, et al. Stability study of dosage form: An inovative step. *World J Pharm Pharm Sci* 2014; 3:1031-50.
10. Freed AL, Colgan ST, Kochling JD, Alasandro MS. Accelerating pharmaceutical development through predictive stability approaches. *AAPS J* 2017;3:2-10.